Eisai Co., Ltd. and Biogen, Inc. will launch their amyloid protofibril-targeting antibody Leqembi (lecanemab), which won accelerated approval from the US Food and Drug Administration on 6 January for treatment of early Alzheimer’s disease, with a different approach to pricing than the partners used for their earlier anti-amyloid antibody, Aduhelm (aducanumab), which the FDA cleared a year and a half ago under the accelerated approval pathway but never gained traction with prescribers and payers.
Eisai leads the commercialization effort and will bring Leqembi to market with a strategy that seems to reflect lessons learned...
